Arcutis Partners with Sato Pharmaceutical to Develop and Commercialize Topical Zoryve (Roflumilast) for Dermatological Indications in Japan
Shots:
- Arcutis & Sato have signed a strategic collaboration & licensing agreement to develop, manufacture & commercialize topical Zoryve for dermatological diseases such as plaque psoriasis, seborrheic dermatitis & atopic dermatitis in Japan
- Under the collaboration, Arcutis is entitled to receive $25M upfront and additional $40M for achieving regulatory & sales milestones plus tiered, low double-digit percentage royalties
- Sato gains exclusive rights to develop, manufacture & commercialize Zoryve cream, foam & other topical presentations in Japan while Arcutis will handle the development & commercialization of its cream & foam formulation across the globe (excl. Greater China & Southeast Asia)
Ref: Arcutis | Image: Arcutis
Related News:- Arcutis Reports the US Launch of Zoryve (roflumilast) Topical Foam, 0.3%, for Treating Seborrheic Dermatitis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
